Re: Trovagene, Inc. Post-Effective Amendment No. 1 to Form S-1 Filed April 25, 2019 File No. 333-224808

Dear Mr. Gabor:

This letter sets forth the response of Trovagene, Inc., a Delaware corporation (the "**Company**" or "we"), to the comment received from the Staff of the Division of Corporation Finance (the "**Staff**") of the Securities and Exchange Commission (the "**Commission**") by letter dated May 9, 2019 ("**Comments Letter**") concerning the Company's Post-Effective Amendment No. 1 to Form S-1 (the "**Registration Statement**").

Post-Effective Amendment No. 1 to Form S-1

General

1. We note that this post-effective amendment seeks to update the prospectuses included in the Form S-1 (333-224808) initially filed on May 10, 2018, and the Form S-1 (333-225510) filed June 8, 2018 in which you registered a primary offering of Class A units, Class B units, and Common Stock issuable upon the exercise of warrants. Since the initial filings did not register a resale offering, it is inappropriate to add a resale offering by means of a post-effective amendment. Please amend your filing to remove the resale offering.

Response: We have amended Post-Effective Amendment No. 1 to Form S-1 to exclude a resale offering.

* * * *

If you have any further comments and/or questions, please contact me at (212) 634-3067.

Very truly yours,

/s/ Jeffrey Fessler